Status:

RECRUITING

Biopsychosocial Markers of Addiction in Opioid Users: an Integrated Approach

Lead Sponsor:

University Hospital, Strasbourg, France

Conditions:

Opioid Use Disorder

Eligibility:

All Genders

18+ years

Brief Summary

Opioid use disorder (OUD) is a chronic and severe psychiatric condition, defined by problematic opioid use, that significantly impairs interpersonal and social functioning. Over the last 10 years, a d...

Detailed Description

First aim of the study is to systematically characterize OUD severity (DSM-5 criteria) and psychosocial factors in N=350 individuals with OUD, recruited at Safe Injection Sites (SIS), and other addict...

Eligibility Criteria

Inclusion

  • Male, female, or transgender person, age \> 18 years
  • French speaking subject, able to understand the objectives and risks of the research
  • Informed signed consent form by the curator (subject under curatorship) / guardian (subject under guardianship), if applicable
  • Subject who has written "I consent" on the consent form
  • Subject using psychoactive substances and who attends a low-risk consumption room (SCMR), or a Center for Care, Accompaniment and Prevention in Addictology (CSAPA), or a Center for Reception and Accompaniment in Harm Reduction for Drug Users (CAARUD)
  • Subject who used one or more illegal opioid drugs or one or more medications (with or without a prescription) at least once in the last 3 months (heroin, buprenorphine, morphine sulfate, methadone, morphine derivatives, oxycontin, oxycodone, oxynorm, Subutex® (Sub), Temgesic®, Suboxone®, Orobupre®, Skenan®, Moscontin®, opium, pethidine, codeine, dinacode, neocodion, codeine efferalgan, Lamaline®, tramadol, durogesic patches, fentanyl...)

Exclusion

  • Inability to give the subject informed information (subject with difficulties in understanding)
  • Subject in an emergency or life-threatening situation
  • Subject under court protection (upon subject's declaration)
  • Subject participating in an investigational drug study (upon subject's declaration)

Key Trial Info

Start Date :

February 7 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 14 2029

Estimated Enrollment :

350 Patients enrolled

Trial Details

Trial ID

NCT06021548

Start Date

February 7 2024

End Date

May 14 2029

Last Update

June 6 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Service Universitaire d'Addictologie, Hospices Civils de Lyon

Bron, France, 69678

2

Centre d'étude des mouvements sociaux (CEMS) UMR8044/INSERM U1276 - École des Hautes Etudes en Sciences Sociales (EHESS)

Paris, France, 75006

3

Service d'Addictologie, Hôpitaux Universitaires de Strasbourg

Strasbourg, France, 67091

Biopsychosocial Markers of Addiction in Opioid Users: an Integrated Approach | DecenTrialz